Oculis (NASDAQ:OCS) Sees Large Volume Increase

Oculis Holding AG (NASDAQ:OCS) saw an uptick in trading volume on Tuesday . 52,187 shares traded hands during mid-day trading, an increase of 11% from the previous session’s volume of 47,215 shares.The stock last traded at $13.25 and had previously closed at $12.73.

Analysts Set New Price Targets

Several brokerages recently weighed in on OCS. Robert W. Baird cut their price target on Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, March 19th. Wedbush restated an “outperform” rating and issued a $29.00 price target on shares of Oculis in a research note on Wednesday, March 6th. HC Wainwright cut their price target on Oculis from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, April 24th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research note on Tuesday, March 19th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $29.14.

Oculis Stock Up 3.0 %

The company has a 50 day simple moving average of $11.86 and a 200 day simple moving average of $11.25. The company has a current ratio of 5.29, a quick ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. Equities research analysts forecast that Oculis Holding AG will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. abrdn plc acquired a new position in Oculis during the fourth quarter worth $15,980,000. Compagnie Lombard Odier SCmA lifted its stake in Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares in the last quarter. Wolverine Asset Management LLC acquired a new position in Oculis during the third quarter worth $77,000. Finally, Searle & CO. acquired a new position in Oculis during the fourth quarter worth $112,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.